HIF1A-AS2 induces osimertinib resistance in lung adenocarcinoma patients by regulating the miR-146b-5p/IL-6/STAT3 axis
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Drug Discovery,Molecular Medicine
Reference31 articles.
1. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020
2. Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice;Martin;Ther. Adv. Med. Oncol.,2017
3. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence;Gridelli;Lung Cancer,2011
4. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment;Chen;Nat. Commun.,2018
5. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma;Karreth;Cell,2011
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions;Cancer Cell International;2024-01-10
2. The regulatory relationship between transcription factor STAT3 and noncoding RNA;Cellular & Molecular Biology Letters;2024-01-03
3. Emerging role of competing endogenous RNA in lung cancer drug resistance;Journal of Chemotherapy;2023-12-20
4. Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs;Drug Resistance Updates;2023-11
5. Long non-coding RNAs in non-small cell lung cancer: implications for preventing therapeutic resistance;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3